IS3863A - Meðferð þreytueinkenna - Google Patents

Meðferð þreytueinkenna

Info

Publication number: IS3863A
Authority: IS; Iceland
Prior art keywords: benzodiazepines; cholinesterase; anxiety; hypnotic; sedative
Prior art date: 1991-05-14

Application number

IS3863A

Other languages

English (en)

Inventor

Snorrason Ernir

Original Assignee

Snorrason Ernir

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-14

Filing date

1992-05-14

Publication date

1992-11-15

1991-05-14 Priority claimed from IS3706A external-priority patent/IS3706A7/is

1992-02-13 Priority claimed from DK18292A external-priority patent/DK18292D0/da

1992-05-14 Application filed by Snorrason Ernir filed Critical Snorrason Ernir

1992-11-15 Publication of IS3863A publication Critical patent/IS3863A/is

Links

206010016256 fatigue Diseases 0.000 title 1
208000024891 symptom Diseases 0.000 title 1
208000019901 Anxiety disease Diseases 0.000 abstract 3
229940049706 benzodiazepine Drugs 0.000 abstract 3
150000001557 benzodiazepines Chemical class 0.000 abstract 3
102100033639 Acetylcholinesterase Human genes 0.000 abstract 2
108010022752 Acetylcholinesterase Proteins 0.000 abstract 2
229940022698 acetylcholinesterase Drugs 0.000 abstract 2
230000003001 depressive effect Effects 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 2
230000000147 hypnotic effect Effects 0.000 abstract 2
230000000241 respiratory effect Effects 0.000 abstract 2
239000000932 sedative agent Substances 0.000 abstract 2
230000001624 sedative effect Effects 0.000 abstract 2
VLGAHTYYCHWLNI-BHRZLAGCSA-N 1w4l Chemical compound O1C(=C23)C(OC)=CC=C2C=[N+](CCCCCCCCN2C(C4=CC=CC=C4C2=O)=O)CC[C@]23[C@@H]1C[C@@H](O)C=C2 VLGAHTYYCHWLNI-BHRZLAGCSA-N 0.000 abstract 1
HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 abstract 1
108010053652 Butyrylcholinesterase Proteins 0.000 abstract 1
LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 abstract 1
102100032404 Cholinesterase Human genes 0.000 abstract 1
229940122041 Cholinesterase inhibitor Drugs 0.000 abstract 1
208000007101 Muscle Cramp Diseases 0.000 abstract 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
206010033670 Panic reaction Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
208000005392 Spasm Diseases 0.000 abstract 1
230000001773 anti-convulsant effect Effects 0.000 abstract 1
230000000561 anti-psychotic effect Effects 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
-1 antipsychotic Substances 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
239000002249 anxiolytic agent Substances 0.000 abstract 1
230000000949 anxiolytic effect Effects 0.000 abstract 1
239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229960003980 galantamine Drugs 0.000 abstract 1
BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 abstract 1
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 1
208000013403 hyperactivity Diseases 0.000 abstract 1
230000002452 interceptive effect Effects 0.000 abstract 1
IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 abstract 1
208000024714 major depressive disease Diseases 0.000 abstract 1
239000003158 myorelaxant agent Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
208000022610 schizoaffective disease Diseases 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Toxicology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Inorganic Compounds Of Heavy Metals (AREA)

IS3863A 1991-05-14 1992-05-14 Meðferð þreytueinkenna IS3863A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IS3706A IS3706A7 (is)	1991-05-14	1991-05-14	Notkun á galantamine-hydróbrómíði í geðlæknisfræði
DK18292A DK18292D0 (da)	1992-02-13	1992-02-13	Method of counteracting adverse effects of benzodiazepines

Publications (1)

Publication Number	Publication Date
IS3863A true IS3863A (is)	1992-11-15

Family

ID=36746635

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS3863A IS3863A (is)	1991-05-14	1992-05-14	Meðferð þreytueinkenna

Country Status (15)

Country	Link
US (3)	US5336675A (is)
EP (3)	EP0879596B8 (is)
JP (2)	JP3778923B2 (is)
AT (2)	ATE336236T1 (is)
CA (2)	CA2103022C (is)
DE (2)	DE69228928T2 (is)
DK (2)	DK0584285T3 (is)
ES (2)	ES2129450T3 (is)
GR (1)	GR3030046T3 (is)
IE (2)	IE921548A1 (is)
IS (1)	IS3863A (is)
NO (2)	NO308125B1 (is)
NZ (1)	NZ242743A (is)
PT (1)	PT879596E (is)
WO (1)	WO1992020328A2 (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1367056A1 (en) *	1992-07-24	2003-12-03	The Regents Of The University Of California	Drugs that enhance synaptic responses mediated by AMPA receptors
DE4301782C1 (de) *	1993-01-23	1994-08-25	Lohmann Therapie Syst Lts	Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
US6323196B1 (en) *	1993-10-15	2001-11-27	Aventis Pharmaceuticals Inc.	Galanthamine derivatives as acetylcholinesterase inhibitors
DE19509663A1 (de)	1995-03-17	1996-09-19	Lohmann Therapie Syst Lts	Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) *	1995-07-19	1995-09-20	Sod Conseils Rech Applic	Galanthamine derivatives
DE19533772C1 (de) *	1995-09-12	1998-01-02	Hexal Ag	Tacrin/Selegilin-Pflaster
GB9519268D0 (en) *	1995-09-21	1995-11-22	Chiroscience Ltd	Preparation of alkaloids
AT402691B (de) *	1996-01-26	1997-07-25	Sanochemia Ltd	Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
AT403803B (de) *	1996-04-19	1998-05-25	Sanochemia Ltd	Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
TW506836B (en) *	1996-06-14	2002-10-21	Janssen Pharmaceutica Nv	Fast-dissolving galanthamine hydrobromide tablet
US5736075A (en) *	1996-10-22	1998-04-07	C.J. Associates, Ltd.	Method of forming a molded product using a freezing step
GB9716879D0 (en) *	1997-08-08	1997-10-15	Shire Int Licensing Bv	Treatment of attention deficit disorders
IT1304904B1 (it) *	1998-09-11	2001-04-05	Eisai Co Ltd	Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
WO2000023057A2 (en) *	1998-10-16	2000-04-27	Janssen Pharmaceutica N.V.	Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition
AU2004242546B2 (en) *	1998-11-23	2008-05-15	Bonnie Davis	Dosage formulations for acetylcholinesterase inhibitors
AU1738800A (en) *	1998-11-23	2000-06-13	Bonnie Davis	Dosage formulations for acetylcholinesterase inhibitors
DE19857716A1 (de) *	1998-12-15	2000-06-21	Bayer Ag	Neue feste Formulierung von Metrifonat
AU775914B2 (en)	1998-12-24	2004-08-19	Janssen Pharmaceutica N.V.	Controlled release galantamine composition
DE19906977C1 (de) *	1999-02-19	2000-06-15	Lohmann Therapie Syst Lts	Desoxypeganin-TTS und seine Verwendung
US20050063998A1 (en) *	1999-10-26	2005-03-24	Francois Marc Karel Jozef	Oral solution containing galantamine and a sweetening agent
NZ516302A (en) *	2000-03-31	2004-02-27	Sanochemia Pharmazeutika Ag	Novel derivatives and analogues of galanthamin
CA2310950C (en) *	2000-04-03	2005-11-08	Janssen Pharmaceutica N.V.	An efficacious dosage regiment of galantamine that reduces side effects
US6673302B2 (en)	2001-01-24	2004-01-06	Scimed Life Systems, Inc.	Wet processing method for catheter balloons
DE10119862A1 (de) *	2001-04-24	2002-11-07	Hf Arzneimittelforsch Gmbh	Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
CA2358148A1 (en) *	2001-10-03	2003-04-03	Mold-Masters Limited	A nozzle
DE10235556A1 (de) *	2002-08-03	2004-02-19	Hf Arzneimittelforschung Gmbh	Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20040067934A1 (en) *	2002-10-03	2004-04-08	Parys Wim Louis Julien	Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2003287433A1 (en) *	2002-11-01	2004-06-07	Oregon Health And Science University	Treatment of hyperkinetic movement disorder with donepezil
AU2004216360B2 (en) *	2003-02-27	2009-09-17	Eisai R & D Management Co., Ltd.	Pharmaceutical composition for treatment of drug dependence
US7297691B2 (en)	2003-08-13	2007-11-20	Janssen Pharmaceutica N.V.	Treatment of sleep disorders with cholinesterase inhibitors
DE10338544B4 (de) *	2003-08-19	2017-08-31	Janssen Pharmaceutica N.V.	Buccale Formulierungen des Galanthamins und deren Anwendungen
BG65658B1 (bg) *	2003-11-13	2009-05-29	"Софарма" Ад	Комбиниран лекарствен продукт на основата на галантамин
DE10354893B4 (de) *	2003-11-24	2011-03-10	Hf Arzneimittelforschung Gmbh	Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
US20050191349A1 (en) *	2003-12-31	2005-09-01	Garth Boehm	Galantamine formulations
US20050142193A1 (en) *	2003-12-31	2005-06-30	Lijuan Tang	Galantamine formulations
WO2005115471A2 (en) *	2004-05-27	2005-12-08	Neurocure Ltd.	Methods and compositions for treatment of nicotine dependence and dementias
WO2006036686A2 (en) *	2004-09-24	2006-04-06	University Of Maryland, Baltimore	Method of treating organophosphorous poisoning
US9132135B2 (en)	2004-09-24	2015-09-15	University Of Maryland, Baltimore	Method of treating organophosphorous poisoning
AU2007299920A1 (en) *	2006-09-19	2008-03-27	Braincells, Inc.	PPAR Mediated Modulation of Neurogenesis
CN101190330A (zh) *	2006-11-30	2008-06-04	深圳市鼎兴生物医药技术开发有限公司	胆碱酯酶在拮抗速激肽药物中的应用
US8110226B2 (en) *	2007-07-20	2012-02-07	Mylan Pharmaceuticals Inc.	Drug formulations having inert sealed cores
CN101842079B (zh) *	2007-08-31	2012-09-05	阿基米德开发有限公司	非水性药物组合物
EP2030610A1 (en) *	2007-08-31	2009-03-04	Archimedes Development Limited	Non-aqueous pharmaceutical compositions
CL2008003507A1 (es) *	2007-11-26	2009-11-27	Neuroderm Ltd	Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
IL301562A (en) *	2020-10-01	2023-05-01	Univ Leland Stanford Junior	Methods and systems for modifying empathy by modulating type 2 theta oscillations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4663318A (en) *	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
EP0363415B1 (en) *	1987-05-04	2008-10-15	Davis, Bonnie	Compounds for the treatment of alzheimer's disease
IL87861A0 (en) *	1987-10-05	1989-03-31	Pfizer	4-aminopyridine derivatives
JP2699511B2 (ja) *	1988-01-29	1998-01-19	武田薬品工業株式会社	置換アミン類
JP2931986B2 (ja) *	1989-02-17	1999-08-09	武田薬品工業株式会社	アラルキルアミン誘導体
KR940003491B1 (ko) *	1989-08-10	1994-04-23	리히터 게데온 베기에스제티 기아르 알.티	4,4-이중 치환된 피페리딘 유도체와 그 제조방법 및 상기 화합물을 함유하는 약제학적 조성물
DE3927049A1 (de) *	1989-08-16	1991-02-21	Sandoz Ag	Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung

1992
- 1992-02-28 US US07/842,322 patent/US5336675A/en not_active Expired - Lifetime
- 1992-05-14 CA CA002103022A patent/CA2103022C/en not_active Expired - Lifetime
- 1992-05-14 EP EP98201818A patent/EP0879596B8/en not_active Expired - Lifetime
- 1992-05-14 CA CA002468449A patent/CA2468449C/en not_active Expired - Lifetime
- 1992-05-14 PT PT98201818T patent/PT879596E/pt unknown
- 1992-05-14 DE DE69228928T patent/DE69228928T2/de not_active Expired - Fee Related
- 1992-05-14 DE DE69233648T patent/DE69233648T2/de not_active Expired - Fee Related
- 1992-05-14 ES ES92917377T patent/ES2129450T3/es not_active Expired - Lifetime
- 1992-05-14 ES ES98201818T patent/ES2270493T3/es not_active Expired - Lifetime
- 1992-05-14 AT AT98201818T patent/ATE336236T1/de not_active IP Right Cessation
- 1992-05-14 DK DK92917377T patent/DK0584285T3/da active
- 1992-05-14 IS IS3863A patent/IS3863A/is unknown
- 1992-05-14 EP EP92610035A patent/EP0515302A1/en active Pending
- 1992-05-14 AT AT92917377T patent/ATE178791T1/de not_active IP Right Cessation
- 1992-05-14 DK DK98201818T patent/DK0879596T3/da active
- 1992-05-14 JP JP51011192A patent/JP3778923B2/ja not_active Expired - Fee Related
- 1992-05-14 EP EP92917377A patent/EP0584285B1/en not_active Expired - Lifetime
- 1992-05-14 WO PCT/DK1992/000161 patent/WO1992020328A2/en not_active Ceased
- 1992-05-14 NZ NZ242743A patent/NZ242743A/en not_active IP Right Cessation
- 1992-07-01 IE IE154892A patent/IE921548A1/en not_active IP Right Cessation
- 1992-07-01 IE IE19990887A patent/IE990887A1/en not_active IP Right Cessation
1993
- 1993-11-12 NO NO934103A patent/NO308125B1/no unknown
1994
- 1994-08-22 US US08/292,230 patent/US5589475A/en not_active Expired - Lifetime
1995
- 1995-06-05 US US08/461,849 patent/US5633238A/en not_active Expired - Fee Related
1998
- 1998-08-27 NO NO19983939A patent/NO322137B1/no unknown
1999
- 1999-04-23 GR GR990401123T patent/GR3030046T3/el unknown
2002
- 2002-02-15 JP JP2002082084A patent/JP2002326959A/ja active Pending

Also Published As

Publication number	Publication date
NO983939L (no)	1993-11-12
JP2002326959A (ja)	2002-11-15
PT879596E (pt)	2007-01-31
WO1992020328A2 (en)	1992-11-26
NZ242743A (en)	1997-02-24
CA2103022C (en)	2006-04-04
GR3030046T3 (en)	1999-07-30
EP0515302A1 (en)	1992-11-25
US5336675A (en)	1994-08-09
NO308125B1 (no)	2000-07-31
ES2270493T3 (es)	2007-04-01
EP0879596B8 (en)	2007-05-23
EP0879596A2 (en)	1998-11-25
DE69228928D1 (de)	1999-05-20
JP3778923B2 (ja)	2006-05-24
NO983939D0 (no)	1998-08-27
CA2468449A1 (en)	1992-11-26
US5589475A (en)	1996-12-31
DE69233648T2 (de)	2007-08-09
US5633238A (en)	1997-05-27
CA2103022A1 (en)	1992-11-15
EP0584285A1 (en)	1994-03-02
CA2468449C (en)	2008-05-13
DE69233648D1 (de)	2006-09-28
DK0879596T3 (da)	2006-12-18
DK0584285T3 (da)	1999-10-25
EP0879596B1 (en)	2006-08-16
NO934103D0 (no)	1993-11-12
ATE178791T1 (de)	1999-04-15
NO322137B1 (no)	2006-08-21
JPH06507621A (ja)	1994-09-01
WO1992020328A3 (en)	1993-04-15
EP0584285B1 (en)	1999-04-14
EP0879596A3 (en)	2000-08-16
NO934103L (no)	1993-11-12
DE69228928T2 (de)	1999-10-28
ES2129450T3 (es)	1999-06-16
AU1873692A (en)	1992-12-30
IE921548A1 (en)	1992-11-18
AU663086B2 (en)	1995-09-28
IE990887A1 (en)	2000-12-13
ATE336236T1 (de)	2006-09-15

Publication	Publication Date	Title
IS3863A (is)	1992-11-15	Meðferð þreytueinkenna
ES2134215T3 (es)	1999-10-01	Tratamiento de sindromes de fatiga con inhibidores de colinesterasa.
MY140557A (en)	2009-12-31	Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
ATE412415T1 (de)	2008-11-15	Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
PA8491901A1 (es)	2001-12-14	Procedimientos e intermedios para preparar compuestos anticancerosos.
PL359340A1 (en)	2004-08-23	Triazole derivatives
ATE257156T1 (de)	2004-01-15	(1,2,4)triazolo(1,5-c)pyrimidin-derivate
GB9921150D0 (en)	1999-11-10	Therapeutic agents
ATE229530T1 (de)	2002-12-15	Tetrahydropyridin-(oder 4-hydroxypiperidin) alkylazole mit sigma und/oder 5ht 1a-rezeptor aktivität
PT912184E (pt)	2002-12-31	Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
BR0210222A (pt)	2004-04-13	Derivado de benzoxazepina, composição farmacêutica, uso de um derivado de benzoxazepina, e, método para tratar uma doença neurológica ou distúrbio psiquiátrico
PT1023291E (pt)	2004-09-30	Derivados de dipiridoimidazole uteis no tratamento de desordens do sistema nervoso central
Zhu et al.	1998	Synthesis of 2, 6, 7-Trichloro-1-(β-d-ribofuranosyl) naphtho [2, 3-d] imidazole: A Linear Dimensional Analogue of the Antiviral Agent TCRB
NO20021041L (no)	2002-04-03	Polymorfismer av N-metyl-N-(3{3-[2-tienylkarbonyl]pyrazol- [1,5-alfa]-pyrimidin-7-yl}fenyl)acetamid og blandinger ogfremgangsmåter relatert dertil
Houlihan et al.	1985	Sleep-inducing N-alkyl-5-[m-(trifluoromethyl) phenyl]-5-hydroxy-2-pyrrolidinones and N-alkyl-3-(trifluoromethyl) cinnamamides
ATE112256T1 (de)	1994-10-15	9-amino-2-phenylbicyclo(3.3.1>nonane und 9-amino- 2-phenylbicyclo(3.3.1>-non-2-ene und diese enthaltende therapeutische mittel.
DK0399653T3 (da)	1994-11-14	Triazolo(4,5-c)pyridinderivater med antikrampe virkning